U.S. COMPANY FILING
AMGEN INC — Form 10-Q filed 2026-08-05
Filing text preview
Amgen's Q2 2026 results show strong revenue growth and improved profitability, driven by higher product sales and lower costs. However, TAVNEOS faces FDA withdrawal risk, and Otezla was impaired due to IRA. Cash flow remains robust, and dividends continue.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record